The proportion of patients with abnormal tumor markers in this study was 31.3% (5/16), including CA153 (1 case), CA199 (1 case), urinary Ig kappa light chain (2 cases), serum β2-microglobulin (2 cases), urinary Ig lambda light chain (1 case), serum Ig kappa light chain (1 case), urinary β2-microglobulin (1 case), AFP (1 case), CA50 (1 case), and serum Ig lambda light chain (1 case). The gene discussed is HLA-G; the disease is neoplasm.